Terminated PHASE2 INTERVENTIONAL 1-arm NCT02670317

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (FIL-GALILEO)

Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients.

Sponsor: Fondazione Italiana Linfomi - ETS

Conditions Lymphoma, B-Cell

Interventions CHOP Ibrutinib Obinutuzumab

Updated 8 times since 2017 Last updated: Mar 16, 2017 Started: Sep 30, 2016 Primary completion: Feb 28, 2017 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

GA101-CHOP not advantage from rituximab-CHOP

Other terminated trials from Fondazione Italiana Linfomi - ETS

See all terminations from Fondazione Italiana Linfomi - ETS

Other Lymphoma, B-Cell trials with similar outcome

Browse all Lymphoma, B-Cell trials

Listed as NCT02670317, this PHASE2 trial focuses on Lymphoma, B-Cell and remains terminated or withdrawn. Sponsored by Fondazione Italiana Linfomi - ETS, it has been updated 8 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jun 2023 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jun 2023 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Apr 2017 — Jun 2018 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Jan 2017 — Apr 2017 [monthly]

Recruiting PHASE2

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione Italiana Linfomi - ETS

Data source: Fondazione Italiana Linfomi - ETS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Bari, Italy , Bergamo, Italy , Bolzano, Italy , Cagliari, Italy , Candiolo, Italy , Cosenza, Italy , Florence, Italy , Lecce, Italy , Meldola, Italy and 17 more locations